Drug Profile
AVI CO 004
Alternative Names: AVI CO 004-Avixgen; AVI-CO-004Latest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Avixgen
- Class Antiretrovirals; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II HIV-1 infections
Most Recent Events
- 07 Dec 2022 AVI CO 004 is still in phase-II clinical trials for HIV-1 infections in South Korea and Vietnam (PO) (Avixgen pipeline, December 2022)
- 08 Dec 2020 Ebixen plans a phase I/II trial for HIV-1 infections in South Korea in August 2020 (KCT0005329)
- 02 Sep 2020 Phase-II clinical trials in HIV-1 infections in South Korea (PO) (Avixgen pipeline, September 2020)